Anti-PD-L1 peptide improves survival in sepsis

Journal of Surgical Research

Volumn 208, Issue , 2017, Pages 33-39

  Shindo, Yuichiro ^a,b,c   McDonough, Jacquelyn S ^a   Chang, Katherine C ^a   Ramachandra, Murali ^d   Sasikumar, Pottayil G ^d   Hotchkiss, Richard S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Aurigene Discovery Technologies Limited   (India)

Author keywords

Immunomodulatory drug; Immunosuppression; Programmed cell death 1; Sepsis; Therapeutic peptide

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PEPTIDE; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; FUNGEMIA; IMMUNOCOMPETENT CELL; MALE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SPLEEN CELL; ANIMAL; CANDIDEMIA; METABOLISM; PRECLINICAL STUDY; SPLEEN;

ANIMALS; ANTIGENS, CD274; CANDIDEMIA; DRUG EVALUATION, PRECLINICAL; MALE; MICE; PEPTIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; SPLEEN;

EID: 84992431086     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2016.08.099     Document Type: Article

References (37)

1. 1 Singer, M., Deutschman, C.S., Seymour, C.W., et al. The Third International Consensus Definitions for sepsis and septic shock (Sepsis-3). JAMA 315 (2016), 801–810.
2. 2 Martin, G.S., Mannino, D.M., Eaton, S., Moss, M., The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003), 1546–1554.
3. 3 Dellinger, R.P., Levy, M.M., Rhodes, A., et al., Surviving Sepsis Campaign Guidelines Committee including the Pediatric, S. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41 (2013), 580–637.
4. 4 Martin, G.S., Mannino, D.M., Moss, M., The effect of age on the development and outcome of adult sepsis. Crit Care Med 34 (2006), 15–21.
5. 5 Kung, H.C., Hoyert, D.L., Xu, J., Murphy, S.L., Deaths: final data for 2005. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 56 (2008), 1–120.
6. 6 Hotchkiss, R.S., Karl, I.E., The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003), 138–150.
7. 7 Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13 (2013), 260–268.
8. 8 Deitch, E.A., Animal models of sepsis and shock: a review and lessons learned. Shock 9 (1998), 1–11.
9. 9 O'Reilly, M., Newcomb, D.E., Remick, D., Endotoxin, sepsis, and the primrose path. Shock 12 (1999), 411–420.
10. 10 Hutchins, N.A., Unsinger, J., Hotchkiss, R.S., Ayala, A., The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 20 (2014), 224–233.
11. 11 Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N Engl J Med 369 (2013), 840–851.
12. 12 Hotchkiss, R.S., Monneret, G., Payen, D., Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13 (2013), 862–874.
13. 13 Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168 (2002), 2493–2500.
14. 14 Hotchkiss, R.S., Tinsley, K.W., Swanson, P.E., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166 (2001), 6952–6963.
15. 15 van Dissel, J.T., van Langevelde, P., Westendorp, R.G., Kwappenberg, K., Frolich, M., Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351 (1998), 950–953.
16. 16 Ertel, W., Kremer, J.P., Kenney, J., et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85 (1995), 1341–1347.
17. 17 Munoz, C., Carlet, J., Fitting, C., Misset, B., Bleriot, J.P., Cavaillon, J.M., Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88 (1991), 1747–1754.
18. 18 Rigato, O., Salomao, R., Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 19 (2003), 113–116.
19. 19 Sinistro, A., Almerighi, C., Ciaprini, C., et al. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccin Immunol 15 (2008), 1851–1858.
20. 20 Chang, K., Svabek, C., Vazquez-Guillamet, C., et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care, 18, 2014, R3.
21. 21 Boomer, J.S., To, K., Chang, K.C., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306 (2011), 2594–2605.
22. 22 Huang, X., Venet, F., Wang, Y.L., et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 106 (2009), 6303–6308.
23. 23 Huang, X., Chen, Y., Chung, C.S., et al. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol 192 (2014), 1091–1099.
24. 24 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
25. 25 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
26. 26 Hotchkiss, R.S., Moldawer, L.L., Parallels between cancer and infectious disease. N Engl J Med 371 (2014), 380–383.
27. 27 Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K.C., McDunn, J.E., Hotchkiss, R.S., Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88 (2010), 233–240.
28. 28 Chang, K.C., Burnham, C.A., Compton, S.M., et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care, 17, 2013, R85.
29. 29 Zhang, Y., Zhou, Y., Lou, J., et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care, 14, 2010, R220.
30. 30 Firer, M.A., Gellerman, G., Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol, 5, 2012, 70.
31. 31 Sasikumar, P.G., Ramachandra, M., Immunosuppression modulating compounds. 2014, Aurigene Discovery Technologies Limited, Bangalore (IN) United State patent US 8,907,053 B2.
32. 32 Davis, C.G., Chang, K., Osborne, D., Walton, A.H., Dunne, W.M., Muenzer, J.T., Increased susceptibility to Candida infection following cecal ligation and puncture. Biochem Biophys Res Commun 414 (2011), 37–43.
33. 33 Unsinger, J., Burnham, C.A., McDonough, J., et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 206 (2012), 606–616.
34. 34 Mikulska, M., Del Bono, V., Ratto, S., Viscoli, C., Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol 8 (2012), 755–765.
35. 35 Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., Honjo, T., A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14 (2013), 1212–1218.
36. 36 Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., Riley, J.L., SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173 (2004), 945–954.
37. 37 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.